Susvimo® (ranibizumab intravitreal injection via ocular implant)

Susvimo is effectively excluded from approval under these guidelines despite its FDA indication for neovascular (wet) AMD in patients who previously responded to ≥2 intravitreal VEGF injections, due to safety concerns including a boxed warning for endophthalmitis. If considered, documentation must show the FDA‑approved diagnosis of wet AMD and prior response to at least two intravitreal VEGF injections.

"When requesting Susvimo (ranibizumab intravitreal injection via ocular implant), the individual requiring treatment must be diagnosed with an FDA-approved indication and meet the specific coverage ..."

Sign up to see full coverage criteria, indications, and limitations.